This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/chemspider/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/chebi/
n18http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/pharmgkb/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00821/identifier/drugbank/

Statements

Subject Item
n2:DB00821
rdf:type
n3:Drug
n3:description
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds. [Wikipedia]
n3:group
approved withdrawn
n3:halfLife
Approximately 8 hours (range 4.5–9.8 hours) in dogs.
n3:indication
For use as a pain reliever in the treatment of joint pain and post-surgical pain.
n3:manufacturer
n9:271B441A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00821 n18:DB00821
dcterms:title
Carprofen
adms:identifier
n6:2483 n7:DB00821 n8:50097346 n10:364453 n12:PA164781361 n13:Carprofen n19:46505357 n20:2581
n3:mechanismOfAction
The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. In an <i>in vitro</i> study using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1.
n3:packager
n9:271B4418-363D-11E5-9242-09173F13E4C5 n9:271B4419-363D-11E5-9242-09173F13E4C5 n9:271B4417-363D-11E5-9242-09173F13E4C5
n3:synonym
Carprofène 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid Carprofeno Carprofen (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid Carprofenum 6-chloro-alpha-Methyl-9H-carbazole-2-acetic acid (+-)-6-chloro-alpha-Methylcarbazole-2-acetic acid
n3:toxicity
Symptoms of NSAID overdose include dizziness and nystagmus. Oral LD<sub>50</sub> in mouse and rat is 282 mg/kg and 149 mg/kg, respectively.
n3:proteinBinding
High (99%)
n3:synthesisReference
Berger, L. and Corraz, A.J.; US. Patent 3,896,145; July 22,1975; assigned to Hoffmann- LaRoche, Inc.
n16:hasConcept
n17:M0049898
n3:IUPAC-Name
n4:271B441F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4425-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4424-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4421-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4422-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4423-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4434-363D-11E5-9242-09173F13E4C5 n4:271B441D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4436-363D-11E5-9242-09173F13E4C5 n4:271B441B-363D-11E5-9242-09173F13E4C5 n4:271B441E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B441C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B442B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B442C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4426-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4427-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4429-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4428-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B442A-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53716-49-7
n3:category
n3:Bioavailability
n4:271B4430-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4432-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4433-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4435-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B442F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B442E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4431-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4420-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B442D-363D-11E5-9242-09173F13E4C5